Inhibition of 11 beta-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

Stefan, Norbert; Ramsauer, Markus; Jordan, Paul; Nowotny, Bettina; Kantartzis, Konstantinos; Machann, Juergen; Hwang, Jong-Hee; Nowotny, Peter; Kahl, Sabine; Harreiter, Juergen; Hornemann, Silke; Sanyal, Arun J.; Stewart, Paul M.; Pfeiffer, Andreas F.; Kautzky-Willer, Alexandra; Roden, Michael; Haering, Hans-Ulrich; Fuerst-Recktenwald, Sabine

Inhibition of 11 beta-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial

Autor(en):

Stefan, Norbert; Ramsauer, Markus; Jordan, Paul; Nowotny, Bettina; Kantartzis, Konstantinos; Machann, Juergen; Hwang, Jong-Hee; Nowotny, Peter; Kahl, Sabine; Harreiter, Juergen; Hornemann, Silke; Sanyal, Arun J.; Stewart, Paul M.; Pfeiffer, Andreas F.; Kautzky-Willer, Alexandra; Roden, Michael; Haering, Hans-Ulrich; Fuerst-Recktenwald, Sabine

Tübinger Autor(en):

Stefan, Norbert
Kantartzis, Konstantinos
Machann, Jürgen
Häring, Hans-Ulrich

Erschienen in:

Lancet Diabetes & Endocrinology (2014), Bd. 2, H. 5, S. 406-416

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S2213-8587(13)70170-0

ISSN:

2213-8587